Tirzepatides dual-action approach stimulates both GLP-1 and GIP receptors, offering a broader span of metabolic benefits and appetite control
More operational details will be forthcoming from CMS in the next few weeks prior to the July 1st launch
Zepbound other than what theyre FDA-approved to treat: Zepbound is approved for weight loss and obstructive sleep apnea
This pathway is active during brain development and plays a role in neural repair after injury
Trial evidence: Tesamorelin 2mg SC daily sustained GH/IGF-1 elevation, 15-18% visceral fat reduction over 6 months (Falutz, NEJM 2007, PMID 17699044) Ipamorelin 200-300 mcg peak GH 5-10x baseline within 30 minutes, no cortisol/prolactin bump (Raun, EJE 1998, PMID 9539826) GHRH + GHRP synergy 2-3x greater amplitude than either alone (Bowers, JCEM 1991, PMID 2004615) Community protocols extend this evidence base with cycling patterns that weren't studied in the original trials the 5-on/2-off rhythm and 8-week cycles are empirical community consensus, not clinically validated
Subcutaneous injection remains the standard and most reliable administration route for glow peptide
